A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Seribantumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 12 Jul 2016 Status changed from active, no longer recruiting to completed.
- 18 May 2016 Results from this and 2 other trials were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.
- 30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History